Founded by Dr. Yug Varma, a Ph.D. bioorganic chemist from Johns Hopkins University, Phyla’s changing the way chronic skin diseases are treated. 

“The microbiome has emerged as one of the most promising and exciting areas in skincare, and we are one of the most mature and proven technologies in this space”, said Dr. Varma. “As we are the first acne product in the market with phage technology, our approach is much more targeted to eliminating the root cause of acne and delivers excellent results without the side effects or relapses seen from other harsh products. We’re proud of the profound impact our technology has had on our customers, and grateful for the overwhelming support they have shown us.” 

‘High Value Investors’

Earlier this year, Phyla hired Neil Giugno as its chief operating and marketing officers. His global CPG marketing and commercial operations background along with his experience building and scaling genetics start-up GenoPalate positions Phyla well as it enters its growth stage.

“As we continue to focus on growth and furthering innovation in acne, we welcome the high value investors who have joined us in this round. We look forward to getting to the next stage of growth with them as our partners around the table,” said Dr Varma. 

Maximum Effort Holdings (the investment firm led by Kevin Law and Ryan Reynolds), Willow Growth, N+1 Ventures, Joyance Partners and Brandon Shainfeld highlight Phyla’s $2 million growth round. Progression Fund, an early investor, also joined the round.